Page 5 - Lupin

Lupin gets USFDA approval to market anti-epilepsy drug in US market

Drug firm Lupin on Friday said it has received approval from the US health regulator to market its anti-epilepsy drug Vigabatrin for Oral Solution in the American market.

Stocks to Watch: Lupin, Jindal Steel, Wipro, Future Group, Tata Steel Long

Lupin may be in focus as it has launched its first Reference Laboratory in East India in Kolkata.

Lupin signs Mary Kom as brand ambassador for its Shakti campaign

Homegrown pharma major Lupin Ltd on Monday said it has signed six-time world boxing champion and Olympics bronze medallist Mary Kom as brand ambassador for its Shakti campaign

Lupin gets FDA nod to market Efinaconazole topical solution in US

Drug major Lupin on Thursday said it has received approval from the US health regulator to market Efinaconazole topical solution, used to treat fungal toenail infections, in the American market

Lupin launches generic medication, to be manufactured in Nagpur, in US

Drug maker Lupin on Tuesday said it has launched Sevelamer Hydrochloride tablets (800 mg), used to treat hyperphosphatemia in patients with chronic kidney disease, in the US market

Sensex dips for 3rd day, slips 59 pts; Ambuja Cement falls 6%, HDFC up 1%

On the sectoral front, key indices ended in the negative zone led by the Nifty Realty index (down 1.2 per cent) and the Nifty Pharma index (down 0.8 per cent).

Lupin receives USFDA approval for antibiotic Solosec

Lupin Ltd on Thursday said it has received approval from the US health regulator for its supplemental New Drug Application (sNDA) for usage of its antibiotic Solosec.

What are Lupin CEO Vinita Gupta's plans for growth in US & China?

In conversation with Business Standard's Sohini Das, Lupin CEO Vinita Gupta shared her company's growth plans in the US and in China. Let us listen in to the interview

TMS Ep104: Brands & politics, Vinita Gupta, markets, Central Vista

Why brands should stay away from politics? What are Lupin CEO's plans for growth in US & China? Can investors benefit from Brent crude rally? What is the Central Vista project? Find all answers here

Lupin slips 9% in two days, hits 52-week low on disappointing Q3 results

In the past six months, the stock has shed nearly 30 per cent, as compared to a 7 per cent rise in the S&P BSE Sensex.

We are working on developing a China pipeline: Lupin CEO Vinita Gupta

Lupin's CEO Vinita Gupta tells Sohini Das about the company's global plans

Lupin consolidated net profit up 24% at Rs 545 crore in Dec quarter

Drugmaker Lupin reported a 24.45 per cent rise in its consolidated net profit at Rs 545.5 crore for the third quarter ended December 31

Lupin slips 5%, nears 52-week low post December quarter results

The company reported lower-than-expected margins and net profit in December quarter due to one-time expenses related to residual metformin returns and provision for aged stock returns of Oseltamivir.

Stocks to Watch: RIL, ITC, TCS, Titan, Cadila, Emami, Lupin, EIH, Tyre

BoI, Devyani Intl, Eveready, FSL, Mahindra Life, Paytm, REC, Siemens, Sintex, SPARC, Tata Steel, Thermax and Vijaya Diagnostics are some of the prominent companies to announce results today.

Sensex snaps 3-day winning run, ends 770 pts down; Nifty tops 17,750

Among sectors, all the key indices ended in the red, led by the Nifty IT index (down 2 per cent) and the Nifty Realty index (down 1.7 per cent). Nifty Auto index was the only gainer, up 0.4 per cent.

Stocks to Watch: HP Adhesives, RBL Bank, Adani Trans, HUL, Lupin, CBI

HP Adhesives is likely to debut with a 20-25 per cent listing gain, as per indications from the GMP

Lupin receives tentative USFDA nod for generic Azilsartan Medoxomil tablets

The tentative approval by the US Food and Drug Administration (USFDA) for the abbreviated new drug application (ANDA) Azilsartan Medoxomil tablets is for strengths of 40 mg and 80 mg

US business rebound key to further upsides in Lupin, VAI may offer relief

Clearance for Goa unit is positive; near-term triggers are new launches and market share gains

Stocks to Watch: ITC, Lupin, ABFRL, Glenmark, NBFCs, Tata group stocks

The RBI on Tuesday introduced a prompt corrective action (PCA) framework for large non-banking financial companies (NBFCs)

US FDA clears Lupin's Goa plant, paves way for new product approvals

Goa plant has an annual capacity of 6 billion units of tablets, capsules or oral suspension drugs. It accounts for 18-20% of firm's US revenue